In an attempt to dissuade physicians from following Express Scripts Holding Co.'s advice to prescribe compounded pyrimethamine/leucovorin as an alternative to Turing Pharmaceuticals AG's high-priced Daraprim (pyrimethamine), Turing is arguing that the combination compound should be considered a risky "unapproved drug."
However, the firm Express Scripts has contracted to fulfill prescriptions for the compounded product, Imprimis Pharmaceuticals Inc., maintained that...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?